SCHEMBL3427856

SCHEMBL3427856

CN(c1ccccc1)S(=O)(=O)c1ccc(Cn2nc(C(=O)NOCc3ccccc3)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 9/20 0.48
CNR1 P21554 1/20 0.44
MCL1 Q07820 1/20 0.44
MCHR1 Q99705 1/20 0.43
LIMK2 P53671 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
SLC16A3 O15427 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
USP30 Q70CQ3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13671614 0.79 PTGER4 (0.55) PTGER4CNR1SLC16A3MEN1ALDH1A1
SCHEMBL4252020 0.77 CNR1 (0.48) PTGER4CNR1MCL1HDAC3HDAC1
SCHEMBL4250971 0.73 CNR1 (0.46) PTGER4CNR1MCL1HDAC3HDAC1
SCHEMBL13865187 0.72 PTGER4 (0.67) PTGER4CNR1MEN1ALDH1A1KMT2A
SCHEMBL4245639 0.71 CA12 (0.45) PTGER4CNR1MCL1HDAC3HDAC1
SCHEMBL1897336 0.71 PTGER4 (0.59) PTGER4CNR1SLC16A3ALDH1A1USP30
SCHEMBL13671617 0.71 CNR1 (0.50) PTGER4CNR1MCL1
SCHEMBL4253143 0.71 CNR1 (0.48) PTGER4CNR1MCL1HDAC3HDAC1
SCHEMBL3428395 0.71 PTGER4 (0.54) PTGER4CNR1MCL1MEN1KMT2A
SCHEMBL3432609 0.71 NPC1 (0.47) PTGER4CNR1MCL1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 PTGER4 3500/4885CNR1 2500/4885MCL1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.